Vivani Medical : 2025 Investor Presentation

Published: 2025-06-17 09:08:06 ET VANI

Published on 06/17/2025 at 09:08

https://www.vivani.com

Vivani Medical, Inc.

Guaranteed Adherence. Better Outcomes.

June 2025

Vivani Executive Leadership Team

Adam Mendelsohn PhD - CEO/Director

Co-founder/Co-inventor of Vivani technology

PhD Bioengineering (UCSF/UC Berkeley)

Management of Technology Certificate at Haas School of Business

Research focused on diabetes treatment

Formerly at Boston Scientific and Minimed

Donald Dwyer, MBA - Chief Business Officer

Former Executive Director at AstraZeneca with leadership roles in regulatory affairs, drug development, commercial and business development

Former Vivani Board observer for AZ

Former PhaseBio Board observer for AZ (prior to IPO)

Former Director at Cephalon and Rhone Poulenc Rorer

Lisa Porter, MD - Chief Medical Officer

Former Chief Medical Officer for Eiger BioPharmaceuticals

and Dance BioPharm

Former VP of Medical Development for Amylin

Former Director at GSK, Global Head of Clinical Strategy for Avandia

Former Board member of ViaCyte, Inc.

Truc Le, MBA - Chief Operations Officer

Numerous COO and Executive Positions at Device and Drug-Device Companies, including:

CTO at Dance BioPharm, COO at Avid Bio

Exec VP at Prima Biomed, Sr. VP at Nektar Therapeutics (responsible for Exubera approval), and Worldwide VP at Johnson & Johnson

Anthony Baldor, MS, MBA - Chief Financial Officer

Former CFO and Head of Business Development at Diakonos Oncology

Former VP Corporate Strategy and Development at 4DMT

Former Research Analyst at Jefferies

Former Venture Capital Principal at BioInnovation Capital and Associate at RMI Partners

3

Vivani Headquarters and GMP Manufacturing Facility

I350 S. Loop Road, Alameda, California since 2023

4

Vivani Medical, Inc.

An innovative, clinical-stage biopharmaceutical company developing a portfolio of ultra long-acting, miniature, drug implants to treat chronic diseases. NanoPortal platform technology enables the design of implants aimed at improving medication non-adherence and tolerability.

Lead programs include NPM-115 (high-dose exenatide) and NPM-139 (semaglutide). These miniature, subdermal, GLP-1 implants are under development for chronic weight management in obese and overweight individuals with once or twice-yearly dosing.

Pipeline also includes IND-cleared NPM-119 (exenatide) implant under development for type 2 diabetes designed for twice-yearly dosing.

5

Multiple potentially transformational milestones are anticipated in 2025 including completion of the First-in-human, LIBERATE-1 trial and availability of top-line data. In addition, acceleration of the NPM-139 (semaglutide implant) program toward clinical development is also anticipated.

Disclaimer

Vivani Medical Inc. published this content on June 17, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 17, 2025 at 13:07 UTC.